A case report highlights a 51-year-old man with stage IV non-small cell lung cancer and brain metastasis who received whole ...

Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

In the last decade, immunotherapy agents changed the treatment landscape for Non-Small Cell Lung Cancer (NSCLC)."BUFFALO, NY ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

The following is a summary of “Association of mutation profiles with metastasis in patients with non-small cell lung cancer,” ...

Frankie Wilson was only 5 years old when her father, Dan, a non-smoker, was diagnosed with Stage IV non-small cell lung ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

In a recent phase 3 trial, SBRT led to similar tumor control and survival outcomes compared with hypofractionated ...

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...